M u

l t

i D

i s

c i

P l

i n

a r


c a

n c

e r


a n

a g

e M

e n


KeY Figures

100 octreotide PET scans/year 15 new patients/year 30 patients under treatment


treatMent, FolloW-uP, rehaBilitation

The screening and follow-up of neuroendocrine tumours today is carried out using octreotide PET scans. The actual treatment given varies according to a patient’s profile and tumour type. In addition to standard chemotherapies, new targeted therapies such as everolimus and sunitinib are used. Inoperable metastatic tumours may be treated with novel approaches such as octreopeptides labelled with radioactive isotopes.

research Clinical research carried out at the Institute in the field of endocrine cancers puts great emphasis on the molecular profiling of tumour types. Taking these and other patient factors into account will make it possible to determine which treatment is most likely to be effective.

introDuction The treatment of neuroendocrine tumours has improved tremendously in recent years, particularly with the development of new technologies such as the octreotide PET scan and new biological therapies.

We apply a broad range of expertise, skills and technologies to determine the most appropriate treatment for each individual patient. Dr ALAin HenDLiSz, Head of the Clinic for endocrine Cancers